Sinonasal hemangiopericytoma caused hypophosphatemic osteomalacia

A case report

Jing Li, MDa, Yuanyuan Huang, MDa, Fuzhou Yang, MDa, Qi Zhang, MDa, Decai Chen, MDa, Qin Wang, MDa,*

Abstract

Rationale: Tumor-induced osteomalacia (TIO) is a rare, paraneoplastic syndrome featured with fibroblast growth factor 23 (FGF23) secretion primarily by benign mesenchymal tumors and sometimes by malignancies. TIO diagnosis and treatment is often delayed because TIO usually has nonspecific generalized bone pain and weakness, and location of TIO tumor is quite challenging. Very few TIO caused by sinonasal hemangiopericytoma have been reported in the literature.

Patient concerns: A 40-year-old Chinese woman presented with diffuse bone pain for more than 1 year. Laboratory examination showed hypophosphatemia, hyperphosphaturia, hypocalcemia, and an elevated serum alkaline phosphatase (ALP) level. Imaging studies revealed low bone mineral density (BMD) and multiple pseudo fractures at the ribs. F-18 fluorodeoxyglucose positron emission tomography was negative in searching for tumors. Because no tumor was located, the patient was treated with oral phosphate, calcium, and alfalcaldiol, and achieved great relief in her symptoms and improvement in BMD. Six years later, the patient had breast cancer surgery and received chemotherapy, and still had hypophosphatemia. During this time, nasopharyngo-fiberscope showed nasal mass in her left nasal cavity. Then she had her nasal polyps removed and surprisingly the serum phosphate became normal.

Diagnoses and interventions: The patient had the nasal mass resected, and pathological diagnosis of the nasal mass was sinonasal hemangiopericytoma. Immunohistochemical analysis was positive for FGF23. Thus the final diagnosis was osteomalacia induced by sinonasal hemangiopericytoma. Phosphate supplementation and alfacalcidol were discontinued.

Outcomes: The patient had normal serum phosphate after 6-month follow-up.

Lessons: By presenting this case, we hope to remind clinicians that in patients with osteomalacia with undetermined reason and intranasal polypoid mass, sinonasal hemangiopericytoma should be suspected.

Abbreviations: ALP = alkaline phosphatase, BMD = bone mineral density, CT = computed tomography, FDG = F-18 fluorodeoxyglucose, FGF23 = fibroblast growth factor 23, PET = positron emission tomography, PMT = phosphaturic mesenchymal tumor, TIO = tumor-induced osteomalacia, VAS = visual analog scale.

Keywords: fibroblast growth factor 23, osteomalacia, phosphate, tumor

1. Introduction

Tumor-induced osteomalacia (TIO) is a rare, paraneoplastic syndrome featured with fibroblast growth factor 23 (FGF23) secretion primarily by benign mesenchymal tumors and some-

Editor: N/A

This research was funded by Science and Technology Fund of Sichuan Province (2015FZ0079, 2016JY0180, and 2015ZJ0109). The authors report no conflicts of interest.

*Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, a Department of Nuclear Medicine, Yaan People’s Hospital, Yaan, Sichuan Province, China.

Correspondence: Qin Wang, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, 37 Guoxue Lane, Chengdu 610041, Sichuan, People’s Republic of China (e-mail: wq3166@163.com).

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Medicine (2018) 97:52(e13849)

Received: 17 September 2018 / Received in final form: 30 November 2018 / Accepted: 5 December 2018

http://dx.doi.org/10.1097/MD.00000000000013849

2. Case report

A 40-year-old Chinese woman presented with diffuse bone pain for more than 1 year. Pain firstly affected her spine, then gradually developed in the ribs, pelvis, sternum, and hips, and was aggravated during activity and weight bearing. She had mild nasal obstruction and occasional pus snot for a few months, and was otherwise healthy. On past medical history, the patient took dexamethasone and prednisone occasionally on her own, and...
was also given intravenous zoledronate once in a regional hospital because she was considered to have osteoporosis-related bony pain, yet had no relief of pain. Her family history is not remarkable. When admitted, she had difficulty in walking and other weight bearing activities. Physical examination showed diffuse bony tenderness, and a visual analog scale score of 8.

Biochemical tests showed hypocalcemia (1.92 mmol/L; normal range: 2.10–2.70 mmol/L), hypophosphatemia (0.17 mmol/L; normal range: 0.81–1.45 mmol/L), an elevated intact parathyroid hormone level (15.26 pmol/L; normal range: 1.60–6.90 pmol/L), and a normal 25-hydroxy vitamin D (100.1 nmol/L; normal range: 47.7–144 nmol/L) and 1,25(OH)2D level (46.82 pmol/L; normal range: 39–193 pmol/L). Studies of bone turnover markers showed an elevated alkaline phosphatase (ALP) level (210 IU/L; normal range: 47–138 IU/L), an elevated bone-specific ALP level (56.97 μg/L; normal range: 11.4–24.6 μg/L), and a decreased collagen type I C-telopeptide (0.242 ng/mL; normal range: 0.299–0.573 ng/mL). 24-Hour urine test revealed a lower limit of normal urinary calcium (2.50 mmol; normal range: 2.5–7.5 mmol), and a remarkably elevated urinary phosphate (31.65 mmol; normal range: 22–48 mmol) with regard to the extremely hypophosphatemia. Her blood gas, renal function, liver function, and hemogram were normal. Urinalysis showed normal specific gravity, a pH of 7.0, and no glycosuria or proteinuria.

Dual-energy x-ray absorptiometry revealed decreased bone mineral density (BMD) with a mean z score of −2.8 in lumbar spine (L1–4), −2.7 and −2.6 in femoral neck and total hip, respectively. Radiography of the spine, pelvis, and extremities showed multiple pseudofractures at the ribs, generalized osteopenia, thinning of the cortex of spine, and coarsened trabeculae. Osteomalacia was considered based on the radiographic features. Given her hyperphosphaturic hypophosphatemia and normal renal tubular function, TIO was highly suspected.

The tumor survey revealed a slightly elevated cancer antigen 153 (24.98 U/ml; normal range: <21 U/ml) and 199 (29.28 U/ml; normal range: <22 U/ml), and normal carcinoembryonic antigen, alpha-fetoprotein and cancer antigen 125. Serum and urine protein electrophoresis were normal. Abdominal ultrasonography revealed renal cyst in the left kidney. PET-computed tomography revealed slight high diffuse F-18 FDG intake in the sternum, spine, and both sides of hip and iliac bone, slightly enlarged spleen, left nasal polyp, and left adnexa cyst. Nasopharyngo-fiberscope showed polypoid mass in the left nasal cavity. FGF23 testing was not available at that time.

The patient had a surgery to remove the nasal polypoid mass in another hospital after discharge, and the pathological findings showed hemorrhagic necrotic polyps. Because no tumor was located, oral phosphate, calcium, and alfalcacidol were prescribed. The patient took these drugs regularly, and symptoms were improved after 1 month. During the follow-up, her serum phosphate fluctuated between 0.35 and 0.62 mmol/L, and serum calcium remained normal. She was able to do daily activities and back to work. She had a dramatic increase of BMD in lumbar (31%), femoral neck (22%), and total hip (18%) in 11 months.

Six years after discharge, the patient was diagnosed with breast cancer (T4N1M1, stage IV). Surgery was performed after 8 cycles of chemotherapy, followed by radiotherapy. Her nasal obstruction relapsed during this period, and nasopharyngo-fiberscope showed nasal mass in her left nasal cavity again. Computed tomography (CT) showed soft tissue mass in the left nasal passage, and bony lesions were not found. Surgery of the mass resection was done 2 months after the breast cancer surgery. Serum phosphate was 0.35 mmol/L the day before the nasal surgery yet was 1.24 mmol/L, 1 month after. Pathological diagnosis of the nasal mass was sinonasal hemangiopericytoma (Fig. 1). Immunohistochemical analysis was positive for FGF23 (Fig. 1). Phosphate supplementation and alfalcacidol were discontinued, and the patient had normal serum phosphate after 6-month follow-up. The patient has provided informed consent for publication of the case.

3. Discussion

We reported a rare case of hyperphosphaturic hypophosphatemic osteomalacia induced by FGF23-secreting sinonasal hemangiopericytoma, which was misdiagnosed with nasal polyps, and thus delayed diagnosis and definitive treatment. Immunohistochemical analysis of FGF23 was performed to confirm that osteomalacia was associated with synthesis of FGF23 by sinonasal hemangiopericytoma. By presenting this case, we hope to remind clinicians that in osteomalacia patients with unknown reason and intranasal polypoid mass, sinonasal hemangiopericytoma should be suspected.

Approximately 70% of tumors leading to TIO were histologically classified as phosphaturic mesenchymal tumor (PMT), and other histological entities were giant cell tumor, osteosarcoma, hemangioma, hemangiopericytoma, and so on.[3] Among them, hemangiopericytoma is one of the most common type,[4] as a study showed that 37 of 105 cases of non–PMT-induced TIO were hemangiopericytomat.[2] The majority of tumors causing TIO were of soft tissue origin, with very few located in nasal sinus. As by far the biggest case series of TIO showed, only 4 cases among 39 patients with TIO were found to have tumor in nasal sinus.[2]

Sinonasal hemangiopericytoma, also known as glomangiopericytoma, is very rare, accounting for <0.5% of sinonasal tumors,[6] and 5% of hemangiopericytoma at any site.[7] Till now, 12 cases of TIO caused by sinonasal hemangiopericytoma have been reported by single case reports, although there might be more reported in case series which were hard to verify the diagnosis. The clinical features of all the cases of TIO caused by sinonasal hemangiopericytoma reported by far are summarized in Table 1.[8–19] To be noticed, sinonasal hemangiopericytoma were unilateral in all cases except one with a mass in right nasal cavity extending into the left one,[8] and 8 cases were in the left side.[9–16] Six cases had regional bony resorption by CT.[8–14] Time for diagnosis was from 2 to 6 years since disease onset. One case reported severe bleeding,[17] and another an amount of bleeding of approximately 300 mL during resection of the sinonasal hemangiopericytoma.[10]

Serum FGF23 measurement is critical to TIO diagnosis, and FGF23 levels are elevated in most patients with TIO. Although FGF23 level was not measured in our case, FGF23 immunohistochemical analysis was performed as a surrogate. As far as we know, only 1 study has tested FGF23 protein expression by immunohistochemical analysis in TIO causative tumors in previous literature, which found FGF23 protein expression in 17 of 20 TIO cases.[20]

Mesenchymal tumors that induce TIO are usually small, slowly growing, and difficult to locate, which makes the diagnosis of TIO quite challenging, as was shown that it took 2 to 6 years to reach the diagnosis since disease onset, and 7 years in our case. Imaging is necessary for almost every patient with TIO to locate tumor. A step-wise approach is suggested which starts with functional imaging, such as 18FDG-PET-CT, octreotide SPECT-
CT, and DOTA-CT, followed by anatomical imaging, such as CT and magnetic resonance imaging. Octreotide or DOTA scan are preferred if available, otherwise PET-CT can be performed as in our case. Study showed that PET-CT had a sensitivity of 71.4% to locate causative tumors. Its sensitivity and specificity is inferior to DOTA scan in studies with small sample size, and similar or even inferior to that of octreoscan. In addition, PET-CT and somatostatin analog imaging can be complementary since some tumors may not be seen with somatostatin analog imaging yet were located by PET-CT. Our case showed that the causative tumor revealed a negative FDG uptake, which may be explained by low aggressiveness of the tumor.

For TIO treatment, surgery of complete tumor resection is the first option. Bleeding during surgery should be concerned that 1 case reported severe bleeding, and another an amount of bleeding of approximately 300 mL during surgery. For those causative tumors were not located, or complete resection were...
impossible, medical treatment should be initiated. Phosphorus and active vitamin D supplementation is commonly used for TIO treatment. Because the majority of causative tumors are of borderline or low-grade malignancy, patients may have long survival by medical treatment without tumor resection. It is notable that chemotherapy is not recommended for patients with TIO, as was shown in our case that chemotherapy for breast cancer did not increase serum phosphorus of this patient.

4. Summary
To conclude, sinonasal hemangiopericytoma is a very rare causative tumor of TIO. A step-wise approach is recommended to locate tumors associated with TIO, which starts with functional imaging followed by anatomical imaging. Serum FGF23 measurement is critical of TIO diagnosis, and immunohistochemistry of FGF23 is positive for the majority of causative tumors. Measurement is critical of TIO diagnosis, and immunohistochemistry of FGF23 is positive for the majority of causative tumors. Surgery is the first option of TIO treatment, and medical treatment is indicated for patients when surgery is not possible. By presenting this case, we hope to remind clinicians that in osteomalacia patients with intranasal polypoid mass, sinonasal hemangiopericytoma should be suspected.

Author contributions
Conceptualization: Jing Li, Qin Wang.
Data curation: Jing Li, Decai Chen, Qin Wang.
Investigation: Jing Li, Yuanyuan Huang, Fuzhou Yang, Qi Zhang, Qin Wang.
Methodology: Yuanyuan Huang.
Project administration: Qin Wang.
Writing – original draft: Jing Li.
Writing – review and editing: Jing Li, Decai Chen, Qin Wang.

References
[1] Florenzano P, Gafni RI, Collins MT. Tumor-induced osteomalacia. Bone Rep 2017;7:90–7.
[2] Jiang Y, Xia WB, Xing XP, et al. Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature. J Bone Miner Res 2012;27:1967–73.
[3] Hautmann AH, Hautmann MG, Kolib O, et al. Tumor-induced osteomalacia: an up-to-date review. Curr Rheumatol Rep 2015;17:512.
[4] Wushou A, Miao XC, Shao ZM. Treatment outcome and prognostic factors of head and neck hemangiopericytoma: meta-analysis. Head Neck 2015;37:1685–90.
[5] Ryan EA, Reiss E. Oncogenous osteomalacia. Review of the world literature of 42 cases and report of two new cases. Am J Med 1984;77:591–12.
[6] Thompson LD, Fanburg-Smith JC, Wenig BM. Borderline and Low Malignant Potential Tumours of Soft Tissues. Pathology and Genetics of Head and Neck Tumours. 2005; IARC Press, Lyon:43–45.
[7] Simmons JC, Rebett EE. Surgical resection of sinonasal hemangiopericytoma involving anterior skull base: case reports and literature review. Am J Otolaryngol 2017;38:87–91.
[8] Lee HK, Sung WW, Solodnik P, et al. Bone scan in tumor-induced osteomalacia. J Nucl Med 1995;36:247–9.
[9] Jamal SA, Dickson BC, Radzianius I. Tumour induced osteomalacia due to a sinonasal hemangiopericytoma: a case report. World J Clin Cases 2013;1:59–63.
[10] Burnand G. Oncogenous osteomalacia. Clin Exp Otorhinolaryngol 2011;4:227–9.
[11] Chang CV, Conde SJ, Luvizotto RA, et al. Oncogenic osteomalacia. Hip Int 2012;22:227–9.
[12] Ghosh S, Sinha R, Bandyopadhyay R, et al. Oncogenous osteomalacia: loss of hypophosphatemia might be the key to avoid misdiagnosis. Arq Bras Endocrinol Metabol 2012;56:570–3.
[13] Cho SI, Do NY, Yu SW, et al. Nasal hemangiopericytoma causing oncogenic osteomalacia. Clin Exp Otorhinolaryngol 2012;5:173–6.
[14] Fuentalloa C, Pinto D, Ballesteros F, et al. Oncogenic hypophosphatemic osteomalacia associated with a nasal hemangiopericytoma. J Clin Rheumatol 2013;19:273–9.
[15] Ray S, Chakraborty PP, Biswas K, et al. Oncogenic osteomalacia caused by a nasal hemangiopericytoma: case report. J Clin Rheumatol 2013;19:273–9.
[16] Reiss D, Jamal S, Kim SA. Tumor induced osteomalacia due to a hemangiopericytoma. The Endocrine Society’s 95th Annual Meeting and Expo, 2013. Available at: http://press.endo.org/doi/abs/10.1210/endo-meetings.2013.BCHVD.5.MON-237. Accessed May 3, 2018.
[17] Ghosh S, Sinha R, Bandyopadhyay R, et al. Oncogenous osteomalacia. J Cancer Res Ther 2009;5:210–2.
[18] Lee GG, Dhong HJ, Park YS, et al. Sinonasal glomangiopericytoma causing oncogenic osteomalacia. Clin Exp Otorhinolaryngol 2014;7:145–8.
[19] Breedwein-Gensler M, Siegal GP. Striking pathology gold: a singular experience with daily reverberations: sinonasal hemangiopericytoma (glomangiopericytoma) and oncogenic osteomalacia. Head Neck Pathol 2012;6:64–74.
[20] Beech TJ, Rokade A, Gittos N, et al. A haemangiopericytoma of the ethmoid sinus causing oncogenic osteomalacia: a case report and review of the literature. Int J Oral Maxillofac Surg 2007;36:956–8.
[21] Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 2004;28:1–30.
[21] Yu WJ, He JW, Fu WZ, et al. Reports of 17 Chinese patients with tumor-induced osteomalacia. J Bone Miner Metab 2017;35:298–307.

[22] El-Maouche D, Sadowski SM, Papadakis GZ, et al. (68)Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J Clin Endocrinol Metab 2016;101:3575–81.

[23] Agrawal K, Bhadada S, Mittal BR, et al. Comparison of 18F-FDG and 68Ga DOTATATE PET/CT in localization of tumor causing oncogenic osteomalacia. Clin Nucl Med 2015;40:66–10.

[24] Minisola S, Peacock M, Fukumoto S, et al. Tumour-induced osteomalacia. Nat Rev Dis Primers 2017;3:17044.